Hospital
Cameron Memorial Community Hospital, INC.
Cameron Memorial Community Hospital, INC. was paid $6.69M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoCAMERON MEMORIAL COMMUNITY HOSPITAL, INC.
ANGOLA, IN 46703
ANGOLA, IN 46703
33aNPI1386683316assigned 06/05/2006
33bProvider typeCritical Access Hospital
28Total paid$6.69M
24GClaims121,232
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Indiana
Rank by total paid#6 of 26
Median peer was paid$4.16M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,239 | $391K | |
| 2019 | 16,333 | $701K | |
| 2020 | 13,409 | $865K | |
| 2021 | 17,467 | $1.23M | |
| 2022 | 22,724 | $1.49M | |
| 2023 | 17,905 | $1.25M | |
| 2024incomplete | 13,155 | $761K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 17,025 | 14,390 | $2.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 6,028 | 4,774 | $833K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 4,947 | 4,345 | $726K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.8% | 4,970 | 4,069 | $520K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.3% | 3,403 | 2,485 | $356K |
| 71045 | Radiologic examination, chest; single view | 3.4% | 1,998 | 1,572 | $231K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.4% | 4,154 | 3,185 | $226K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.9% | 1,483 | 1,317 | $193K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.9% | 918 | 865 | $125K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 1.8% | 958 | 493 | $119K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.3% | 3,140 | 2,764 | $84K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 861 | 707 | $84K |
75 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,026 | $80K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 448 | $68K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,024 | $61K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 373 | $52K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,649 | $50K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 302 | $36K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 493 | $34K |
| 87400 | <1% | 3,614 | $31K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 808 | $30K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,371 | $28K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,796 | $24K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 900 | $22K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 184 | $21K |
| 84484 | <1% | 2,956 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 556 | $16K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 174 | $15K |
| 80053 | Comprehensive metabolic panel | <1% | 2,304 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 298 | $12K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 84 | $9K |
| 81001 | <1% | 4,248 | $8K | |
| 83690 | <1% | 2,047 | $7K | |
| 92567 | <1% | 188 | $7K | |
| 80076 | <1% | 1,649 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 70 | $6K |
| 95117 | <1% | 50 | $5K | |
| 92557 | <1% | 37 | $5K | |
| 83735 | <1% | 1,069 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 72 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 100 | $3K |
| 84703 | <1% | 554 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 225 | $2K |
| 80305 | <1% | 283 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 137 | $2K |
| 80320 | <1% | 35 | $2K | |
| 80061 | Lipid panel | <1% | 344 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 60 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 59 | $2K |
| 85027 | <1% | 304 | $1K | |
| 81003 | <1% | 767 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 159 | $796.76 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 170 | $710.37 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 67 | $651.20 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 17 | $624.62 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 72 | $607.89 |
| 86592 | <1% | 148 | $508.37 | |
| 88142 | <1% | 29 | $399.50 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $288.96 |
| 87040 | <1% | 74 | $240.72 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 15 | $175.65 |
| 86803 | <1% | 13 | $171.24 | |
| 82800 | <1% | 56 | $138.71 | |
| 83605 | <1% | 93 | $132.59 | |
| J3490 | Unclassified drugs | <1% | 254 | $116.67 |
| 84146 | <1% | 38 | $77.52 | |
| 84481 | <1% | 39 | $67.76 | |
| 82607 | <1% | 39 | $60.32 | |
| 82553 | <1% | 66 | $58.78 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 142 | $49.00 |
| 82550 | <1% | 81 | $44.43 | |
| 85379 | <1% | 15 | $36.54 | |
| 84439 | <1% | 39 | $36.08 | |
| 82728 | <1% | 28 | $27.26 | |
| 82248 | <1% | 38 | $20.08 | |
| 83550 | <1% | 26 | $17.48 | |
| 83540 | <1% | 27 | $12.94 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,012 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 127 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 224 | $0.00 |
| A9270 | Non-covered item or service | 0% | 70 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 131 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 32 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 18 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 223 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 77 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALDRED, ANDREW (VP/COO)